Clinical Trials Logo

Clinical Trial Summary

This study aims to assess the the role of cardiac biomarkers (troponin and ProBNP) in pediatric Patients with all types of cardiomyopathy in correlation with echocardiography findings .


Clinical Trial Description

Cardiomyopathy are structural or functional abnormalities of the myocardium not secondary to congenital, valvular, hypertensive, pulmonary, or coronary heart diseases . Cardiomyopathy has traditionally been classified into three types based on anatomic and functional features: hypertrophy, dilated, and restrictive. In 1995, two other categories were added by the World Health Organization (WHO), namely, arrhythmical right ventricular cardiomyopathy (dysplasia) (ARVC & ARCD) and unclassified cardiomyopathy . Over the ensuing years, however, other organizations have proposed or classified cardiomyopathy that emphasize the genetics aspect of the disease. The original three types of cardiomyopathy are functionally different from one another, and demands of therapy also are different . In recent years, biomarkers have emerged as important tools for diagnosis, risk stratification and therapeutic decision making in cardiovascular diseases . Cardiac troponins in particular have become the cornerstone for diagnostic work up of patients with cardiomyopathy. Currently, several promising new biomarkers are under scientific investigation. Most of these new biomarkers, however, are not yet suitable for clinical application, with exception of B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-ProBNP). Both markers have proven their diagnostic usefulness in a great number of studies and thus have progressed from bench to clinical application . This study aims to summarize existing data concerning troponins and NT-ProBNP measurement in pediatric with cardiomyopathy and to outline how these markers can be integrated into clinical routine. * THE BIOLOGY OF TROPONIN: The 3-unit troponin complex (troponin I, T and C) along with tropomyosin is located on the actin filament and is essential for calcium -mediated regulation of skeletal and cardiac muscle contraction. There is tissue - specific isoforms of troponin I, T and C. Because the cardiac isoform of troponin C is shared by slow-twitch skeletal muscles, troponin C does not have cardiac specificity and thus is not used in assays of the diagnosis of cardiac injury . There is one cardiac troponin I (cTn I) isoform in myocardial tissue. This isoform has post-translation tail of 32 amino acids on the N-terminus. This sequence and the 42% and 45% dissimilarity with sequences of other isoforms have made possible the generation of highly specific monoclonal anti-bodies without cross-reactivity with other non-cardiac forms . Subtypes of troponin (cardiac I and T) are sensitive and specific indicators of heart muscle damage (myocardium). * B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine: B-type natriuretic peptide, which is also called brain-type natriuretic peptide (BNP), was first described in 1988 after isolation from porcine brain. However, it was soon found to originate mainly from the heart, representing a cardiac hormone. BNP belongs to the natriuretic peptide family together with other structurally similar peptides, namely atrial natriuretic peptides (ANP), C-type natriuretic peptide (CNP), and Urodilatin . The natriuretic peptides have in common a characteristic biochemical structure which consists of a 17 amino acid ring and a disulfide bridge between two cysteine molecules. The major source of BNP synthesis and secretion is the ventricular myocardium. Whereas ANP is stored in granules and can be released immediately after stimulation, only small amounts of BNP are stored in granules and rapid gene expression with de novo synthesis of the peptide is the underlying mechanism of the regulation of BNP secretion . BNP is synthesized as a prohormone (proBNP) comprising 108 amino acids. Upon release into the circulation it is cleaved in equal proportions into the biologically active 32 amino acid BNP, which represents the C-terminal fragment, and the biologically inactive 76 amino acid N-terminal fragment (NT-proBNP). Both molecules are constantly released and can be detected in the blood. The main stimulus for increased BNP and NT-proBNP synthesis and secretion is myocardial wall stress . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06348732
Study type Observational
Source Assiut University
Contact mahmoud ramadan badawy Hussein, MASTER
Phone +2 01098131360
Email drmahmoud.lih@gmail.com
Status Not yet recruiting
Phase
Start date September 1, 2024
Completion date November 2025

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05428787 - Resynchronization in Patients With HF in AF Trial Undergoing Pace & AVNA Strategy With LBBAP Compared With BiV Pacing N/A
Not yet recruiting NCT05567445 - Outcome of Cardiomyopathic Adults Admission in ICU.
Completed NCT02555527 - Contrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus Assessment N/A
Completed NCT00371891 - Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Phase 4
Recruiting NCT05552521 - Diastolic Dysfunction in Septic Shock and Cardiomyopathy Genetic Variants
Recruiting NCT04166331 - Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion Phase 3
Terminated NCT06331507 - Refinement and Assessment of New MRI Technologies for Cardiovascular Exams Using the Phillips CMR Patch N/A
Completed NCT01953523 - Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions N/A
Recruiting NCT04695119 - Sepsis in the ICU-II
Completed NCT03228966 - Ped HIV - Echo Study: Kenya
Recruiting NCT05556369 - Genetic Characterization of Cardiomyopathies (POLICARDIOMIO2021)
Recruiting NCT04520646 - A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy N/A
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Completed NCT04323852 - Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery? Phase 4
Completed NCT03527381 - Nitric Oxide in Cardiopulmonary Bypass for Renal Protection in Cardiac Surgery Phase 1/Phase 2
Withdrawn NCT02462213 - Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging N/A
Active, not recruiting NCT00418041 - Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study) N/A
Not yet recruiting NCT06091475 - Therapy to Maintain Remission in Dilated Cardiomyopathy N/A
Recruiting NCT03317964 - Genetic Basis of Pacing-induced Cardiomyopathy
Terminated NCT03704701 - The Interrogation of the Cardiomyopathy of Chronic Kidney Disease With advancEd caRdiac Imaging